Facility Spotlight: Deeside, Wales, UK

06th Sep 2022

World-class bioconjugation services to support early phase ADC development

Deeside at a glance

Established 2011

53 employees

6,500m2 site

Contributed to 4 of 12 commercially
available ADCs

Developed and transferred
12 clinical processes into GMP

Comprehensive services for a wide range of project requirements.

The Deeside facility delivers more than 10 years of expertise in ADC discovery and development, as well as GMP clinical manufacturing.

Key services include:

Mass spectrometry
Proof of concept
Process development
Process scale-up

Advanced equipment to maximise your success.

Sterling’s Deeside site is home to an array of specialised equipment for bioconjugation projects.

Key equipment includes:

Glove box isolators, <2ng/m3
AKTA chromatography systems
Multiple vendor TFF systems with data logging
Scalable reaction systems
Agilent HPLCs with DAD and chilled autosamplers
Sciex x500B QTOF mass spectrometer

ProteinSimple Maurice for cIEF and CE-SDS
UV/Vis spectrophotometry
Multimodal plate readers for colorimetric and fluorescence assays
Pressure cascade containment, vented cabinets, and 100% HEPA filtered exhausted air

More than a traditional CDMO.

At Sterling, we are committed to working in true scientific partnership with our customers to fully understand their project requirements and maximise their success. That’s why we are a PDMO®, or partnership development and manufacturing organisation.

This means:


We pride ourselves on being easy to do business with, removing layers of complexity, maximising flexibility and scalability to your requirements, and doing what we say we will do, again and again.


We promise to treat your molecule as our own, drive progress by continually exploring new and emerging capabilities, and do the right thing for our people and planet.


We combine our expertise in complex and hazardous chemistry, our world-class facilities and our full-lifecycle capabilities to place scientific excellence at the core of every solution we deliver.

Entirely dedicated to discovery, development and manufacture for antibody drug conjugates, Sterling’s Deeside facility supports a wide range of bioconjugation services. Home to Sterling’s expert bioconjugation team, which was established in 2011 and moved to this state-of-the-art facility in 2018, the Deeside site is designed specifically to handle bioconjugations while maintaining outstanding quality and safety.

Here are some of the things you should know about our Deeside facility:

Purpose-built to handle highly potent bioconjugations, the Deeside facility delivers the containment necessary to maximise both safety and quality in ADC projects. With purpose-built process and analytical development laboratories, the Deeside site provides the capabilities and expertise to support cGMP manufacturing for bioconjugates. Through Sterling’s robust facility network, we can also provide early phase services from our Cary, US site and high potency services from our Germantown, US site as part of one, integrated project.

Established in 2011, our team’s experience working with a variety of targeting molecules, linkers, conjugation chemistries and toxins enables us to help customers develop tailored ADCs. Our team is dedicated to providing excellent service, working with customers in true scientific partnership to overcome challenges and enhance their success.

Sterling continues to invest in the Deeside facility to add additional expert team members and technical capabilities, including the ability to support ADCs throughout their entire lifecycle. In addition, this site provides comprehensive analytical services, including mass spectrometry, to further support the development of transformative therapeutics.

Are you ready to work with an experienced bioconjugation partner?

Related Content

Deeside, Wales, UK

Sterling Pharma Solutions acquires ADC Bio site in Deeside, Wales, UK

ADC Analytical Services